Merkliste 
 1 Ergebnisse 
 
1

Tislelizumab vs Sorafenib as First-Line Treatment for Unres..:

Qin, Shukui ; Kudo, Masatoshi ; Meyer, Tim...
https://discovery.ucl.ac.uk/id/eprint/10178773/1/jamaoncology_qin_2023_oi_230052_1695408988.65364.pdf.  , 2023